# The Myocet/Lapatinib Study. ICORG 10-03, V5

> **NCT01495884** · PHASE1,PHASE2 · TERMINATED · sponsor: **Cancer Trials Ireland** · enrollment: 11 (actual)

## Conditions studied

- Her2 Positive Metastatic Breast Cancer

## Interventions

- **DRUG:** non-pegylated liposomal doxorubicon (Myocet™)
- **DRUG:** Lapatinib (Tyverb™)

## Key facts

- **NCT ID:** NCT01495884
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-03
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Slower than anticipated accrual
- **Last updated:** 2015-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01495884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01495884, "The Myocet/Lapatinib Study. ICORG 10-03, V5". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01495884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*